Dublin, May 16, 2023 (GLOBE NEWSWIRE) -- The "Idiopathic Pulmonary Fibrosis (IPF) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape" report has been added to ResearchAndMarkets.com's offering.
This reports provides a data-driven overview of the current and future competitive landscape in IPF therapeutics.
- There will be more than 0.49 million diagnosed prevalent cases of IPF in 2023 in the 16 countries covered in the publisher's epidemiology forecast for IPF
- Currently, there are two leading marketed drugs for the treatment of IPF, with Roche and Boehringer Ingelheim being key players in the disease space
- R&D activity in IPF is steady, with one product in pre-registration stage and three products in Phase III development
- Commercial sponsors dominate clinical trial development in IPF, with the US emerging as the key country for conducting trials in this disease space
- Globally, deals involving partnerships were the most common type of deals involving companies developing
- There will be more than 0.49 million diagnosed prevalent cases of IPF in 2023 in the 16 countries covered in the publisher's epidemiology forecast for IPF
- Currently, there are two leading marketed drugs for the treatment of IPF, with Roche and Boehringer Ingelheim being key players in the disease space
- R&D activity in IPF is steady, with one product in pre-registration stage and three products in Phase III development
- Commercial sponsors dominate clinical trial development in IPF, with the US emerging as the key country for conducting trials in this disease space
- Globally, deals involving partnerships were the most common type of deals involving companies developing IPF assets
Components of the report include:
- Disease Landscape
- Disease Overview
- Epidemiology Overview
- Treatment Overview
- Marketed Products Assessment
- Breakdown by Mechanism of Action, Molecule Type, Route of Administration
- Product Profiles with Sales Forecast
- Pricing and Reimbursement Assessment
- Annual Therapy Cost
- Time to Pricing and Time to Reimbursement
- Pipeline Assessment
- Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
- Product Profiles with Sales Forecast
- Late-to-mid-stage Pipeline Drugs
- Phase Transition Success Rate and Likelihood of Approval
- Clinical Trials Assessment
- Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
- Enrolment Analytics, Site Analytics, Feasibility Analysis
- Deals Landscape
- Mergers, Acquisitions, and Strategic Alliances by Region
- Overview of Recent Deals
- Commercial Assessment
- Key Market Players
- Future Market Catalysts
Key Topics Covered:
1 Preface
1.1 Contents
1.2 Report Scope
1.3 List of Tables and Figures
1.4 Abbreviations
2 Key Findings
3 Disease Landscape
3.1 Disease Overview
3.2 Epidemiology Overview
3.3 Treatment Overview
4 Marketed Drugs Assessment
4.1 Leading Marketed Drugs
4.2 Overview by Mechanism of Action
4.3 Overview by Route of Administration
4.4 Marketed Drugs Profiles and Sales Forecasts
5 Pricing and Reimbursement Assessment
5.1 Annual Therapy Cost
5.2 Time to Pricing and Reimbursement
6 Pipeline Drugs Assessment
6.1 Phase III Pipeline Drugs
6.2 Overview by Development Stage
6.3 Overview by Molecule Type
6.4 Overview by Mechanism of Action
6.5 Overview by Route of Administration
6.6 Drug Specific Phase Transition Success Rate (PTSR) and Likelihood of Approval (LoA)
6.7 Therapy Area and Indication-specific PTSR and LoA
7 Clinical Trials Assessment
7.1 Historical Overview
7.2 Overview by Phase
7.3 Overview by Status
7.4 Overview by Phase for Ongoing and Planned Trials
7.5 Trials with Virtual Components
7.6 Geographic Overview
7.7 Single-Country and Multinational Trials by Region
7.8 Top 20 Sponsors with Breakdown by Phase
7.9 Top 20 Sponsors with Breakdown by Status
7.10 Overview by Endpoint Status
7.11 Overview by Race and Ethnicity
7.12 Enrollment Data
7.13 Top 20 countries for Trial Sites
7.14 Top 20 Sites Globally
7.15 Feasibility Analysis - Geographic Overview
7.16 Feasibility Analysis - Benchmark Models
8 Deals Landscape
8.1 Mergers, Acquisitions, and Strategic Alliances by Region
8.2 Recent Mergers, Acquisitions, and Strategic Alliances
9 Commercial Assessment
9.1 Key Market Players
10 Future Market Catalysts
11 Appendix
For more information about this report visit https://www.researchandmarkets.com/r/qdtqq1
Source: GlobalData
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
